Adma Biologics (ADMA) Operating Expenses (2011 - 2026)

Adma Biologics (ADMA) has 13 years of Operating Expenses data on file, last reported at $26.1 million in Q4 2025.

• Quarterly Operating Expenses rose 4.22% year-over-year to $26.1 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $101.3 million (up 25.76% YoY) and the FY2025 annual result came in at $101.3 million, up 25.76% from the prior year.
• Operating Expenses rose to $26.1 million in Q4 2025, from $24.6 million in the prior quarter.
• In the past five years, Operating Expenses ranged from a high of $26.2 million in Q1 2025 to a low of $13.4 million in Q1 2021.
• A 5-year average of $19.2 million and a median of $17.8 million in 2023 frame the typical range for Operating Expenses.
• The widest YoY moves for Operating Expenses: up 155.46% in 2021, down 50.16% in 2021.
• Tracing ADMA's Operating Expenses over 5 years: stood at $16.7 million in 2021, then climbed by 21.15% to $20.2 million in 2022, then slipped by 16.72% to $16.9 million in 2023, then jumped by 48.4% to $25.0 million in 2024, then grew by 4.22% to $26.1 million in 2025.
• The last three Operating Expenses figures came in at $26.1 million (Q4 2025), $24.6 million (Q3 2025), and $24.4 million (Q2 2025), per Business Quant data.